Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT): Methods of a prospective...

Area of Science:

• Vascular Medicine
• Hematology
• Pharmacology

Background:

• Upper extremity deep vein thrombosis (UEDVT) is a growing concern, often linked to central venous catheter use.
• Current UEDVT treatment guidelines primarily rely on data from lower extremity deep vein thrombosis (DVT), with limited evidence for direct oral anticoagulants.
• There is a need for evidence-based treatment strategies for UEDVT.

Purpose of the Study:

• To evaluate the efficacy and safety of apixaban for treating upper extremity deep vein thrombosis (UEDVT).
• To determine if apixaban is non-inferior to existing treatments for UEDVT in preventing recurrent venous thromboembolism (VTE) and VTE-related death.

Main Methods:

• A prospective study involving patients with symptomatic UEDVT across two healthcare systems.
• Patients received apixaban 10 mg twice daily for 7 days, followed by 5 mg twice daily for 11 weeks.
• The study compared the 90-day rate of new or recurrent VTE and VTE-related death against a historical threshold of 4%.

Main Results:

• The primary efficacy outcome was the 90-day rate of new or recurrent objectively confirmed symptomatic venous thrombosis and VTE-related death.
• The primary safety outcome assessed was the composite of major and clinically relevant non-major bleeding events.
• A sample size of 375 patients was chosen to ensure statistical power to exclude a 4% event rate.

Conclusions:

• Apixaban demonstrates potential as a safe and effective treatment for upper extremity deep vein thrombosis (UEDVT).
• This study provides evidence supporting the use of direct oral anticoagulants for UEDVT management.
• Further research may solidify apixaban's role in UEDVT treatment protocols.